Colonomics aims to identify useful biomarkers of diagnosis and prognosis in colorectal cancer.
Our long term interest is to improve diagnostic tests for screening of colorectal cancer using biomarkers that complement the detection of occult blood. Also, to provide biomarkers useful to predict recurrence in stage II colorectal cancer. These patients could benefit from adjuvant chemotherapy.
The analysis of complex data analyzed in our tumors including genome-wide SNPs, CNVs, RNA expression, miRNAs and DNA methylation, combined with external sources using systems biology techniques, will enable us to better understand the mechanisms underlying colorectal cancer.